blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2352508

EP2352508 - MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.02.2015
Database last updated on 06.07.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
For all designated states
GENUS ONCOLOGY, LLC
3 Hawthorn Parkway, Suite 250
Vernon Hills, IL 60061 / US
[2014/14]
Former [2011/46]For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
For all designated states
GENUS ONCOLOGY, LLC
3 Hawthorn Parkway, Suite 250
Vernon Hills, IL 60061 / US
Former [2011/32]For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02115-5450 / US
For all designated states
GENUS ONCOLOGY, LLC
3 Hawthorn Parkway, Suite 250
Vernon Hills, IL 60061 / US
Inventor(s)01 / KUFE, Donald, W.
179 Grove Street
Wellesley MA 02482 / US
02 / KHARBANDA, Surender
8 Jacqueline Circle
Natick MA 01760 / US
 [2011/32]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2014/14]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG / GB
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2011/32]Wright, Andrew John
Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date09740811.616.10.2009
[2011/32]
WO2009US61051
Priority number, dateUS20090177109P11.05.2009         Original published format: US 177109 P
US20080106380P17.10.2008         Original published format: US 106380 P
[2011/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010045586
Date:22.04.2010
Language:EN
[2010/16]
Type: A2 Application without search report 
No.:EP2352508
Date:10.08.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.2010 takes the place of the publication of the European patent application.
[2011/32]
Type: B1 Patent specification 
No.:EP2352508
Date:02.04.2014
Language:EN
[2014/14]
Search report(s)International search report - published on:EP13.01.2011
ClassificationIPC:A61K38/17, C07K7/64, C07K14/47, A61P35/00
[2012/40]
CPC:
C07K14/4727 (EP,US); A61K38/17 (KR); A61K38/00 (EP,KR,US);
A61K38/16 (KR); A61K38/1735 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61P43/00 (EP); C07K14/47 (KR);
C07K7/06 (EP,US); C07K7/64 (KR) (-)
Former IPC [2011/32]A61K38/17, C07K7/64, C07K14/47
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/32]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:ZYTOPLASMATISCHE MUC-1-DOMÄNE-PEPTIDE ALS KREBSINHIBITOREN[2011/32]
English:MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER[2011/32]
French:PEPTIDES À DOMAINE CYTOPLASMIQUE MUC-1 EN TANT QU'INHIBITEURS DU CANCER[2011/32]
Entry into regional phase16.05.2011National basic fee paid 
16.05.2011Designation fee(s) paid 
16.05.2011Examination fee paid 
Examination procedure16.05.2011Examination requested  [2011/32]
15.12.2011Amendment by applicant (claims and/or description)
22.06.2012Despatch of a communication from the examining division (Time limit: M02)
20.08.2012Reply to a communication from the examining division
25.07.2013Communication of intention to grant the patent
03.12.2013Fee for grant paid
03.12.2013Fee for publishing/printing paid
Divisional application(s)EP13194715.2  / EP2727601
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.06.2012
Opposition(s)06.01.2015No opposition filed within time limit [2015/11]
Fees paidRenewal fee
25.10.2011Renewal fee patent year 03
26.10.2012Renewal fee patent year 04
30.10.2013Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
MK02.04.2014
MT02.04.2014
RO02.04.2014
SI02.04.2014
SK02.04.2014
SM02.04.2014
BG02.07.2014
[2018/30]
Former [2016/33]CY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
MT02.04.2014
RO02.04.2014
SI02.04.2014
SK02.04.2014
SM02.04.2014
BG02.07.2014
Former [2016/22]CY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
RO02.04.2014
SI02.04.2014
SK02.04.2014
SM02.04.2014
BG02.07.2014
Former [2015/36]CY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
RO02.04.2014
SI02.04.2014
SK02.04.2014
BG02.07.2014
Former [2015/11]CY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
RO02.04.2014
SK02.04.2014
BG02.07.2014
Former [2015/10]CY02.04.2014
CZ02.04.2014
EE02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
SK02.04.2014
BG02.07.2014
Former [2014/50]CY02.04.2014
CZ02.04.2014
HR02.04.2014
LT02.04.2014
LV02.04.2014
BG02.07.2014
Former [2014/48]CY02.04.2014
CZ02.04.2014
LT02.04.2014
BG02.07.2014
Former [2014/47]CY02.04.2014
Cited inInternational search[A]WO0157068  (AUSTIN RESEARCH INST [AU], et al) [A] 1-50 * pages 34,36; claim 11; tables 1,3 *;
 [XPI]  - Donald Kufe, "Award Number: W81XWH-08-1-0093", (20090331), DTIC Online, URL: http://handle.dtic.mil/100.2/ADA503973, (20101012), XP002604939 [XP] 1-7,10,25,28-31,33,38-46 * Front page, Report Documentation, Table of Contents and pages 1-6 * [I] 8,9,11-24,26,27,32,34,35,37,47-50
 [XPI]  - RAINA DEEPAK ET AL, "Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.", CANCER RESEARCH, (20090615), vol. 69, no. 12, ISSN 1538-7445, pages 5133 - 5141, XP002604940 [XP] 1-10,17-22,25,28-31,33,38-46 * the whole document * [I] 11-16,23,24,26,27,32,34,35,37,47-50

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-0854
 [ID]  - LENG YUMEI ET AL, "Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20070706), vol. 282, no. 27, ISSN 0021-9258, pages 19321 - 19330, XP002604941 [ID] 1-50 * the whole document *

DOI:   http://dx.doi.org/10.1074//JBC.M703222200
 [A]  - HU XIU FENG ET AL, "MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma.", EXPERT REVIEW OF ANTICANCER THERAPY, (200608), vol. 6, no. 8, ISSN 1744-8328, pages 1261 - 1271, XP009139935 [A] 1-50 * the whole document *
 [A]  - LI Y ET AL, "MUC1 is a promising therapeutic target for prostate cancer therapy", CURRENT CANCER DRUG TARGETS, (200705), vol. 7, no. 3, ISSN 1568-0096, pages 259 - 271, XP009139934 [A] 1-50 * the whole document *
 [A]  - TSUTSUMIDA HIDEAKI ET AL, "RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20060515), vol. 12, no. 10, doi:10.1158/1078-0432.CCR-05-1197, ISSN 1078-0432, pages 2976 - 2987, XP002489768 [A] 1-50 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-05-1197
 [A]  - REN J ET AL, "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents", CANCER CELL, CELL PRESS, US, vol. 5, no. 2, doi:10.1016/S1535-6108(04)00020-0, ISSN 1535-6108, (20040201), pages 163 - 175, (20040226), XP002565582 [A] 1-50 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1535-6108(04)00020-0
by applicantUS5440013
 US5446128
 US5475085
 US5618914
 US5670155
 US5672681
 US5674976
 US5710245
 US5840833
 US5859184
 US5929237
 US7183059
 US7192713
    - SCHAFMEISTER, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2000), vol. 122, no. 24, pages 5891 - 5892
    - Remington's Pharmaceutical Sciences, pages 624 - 652
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.